DAB2IP and prostate cancer: Based on the numerical data included in the opening introductory paragraph of this manuscript and our observation that about one‐fourth of high‐risk prostate cancer patients have decreased expression of DAB2IP, we estimate that between 12,000 and 18,000 men treated annually in the United States have suboptimal response to the current standard of care treatment.